BackStrategic Partners A/S Overview

Strategic Partners A/S Profit Margin

Valuation check: OZYMF's profit margin is -485.57%, below the Healthcare sector average of 21.34%.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

1019.00%

As of Jun 2026

Annual Profit Margin (TTM)

-485.57%

Trailing 12 months ending Jun 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

Strategic Partners A/S (OZYMF) FAQ

Strategic Partners A/S (OZYMF) currently reports a profit margin of -485.57% as of June 2026. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore Strategic Partners A/S's profit margin history and peer comparisons.

Strategic Partners A/S's profit margin of -485.57% is lower than the Healthcare sector average of 21.34%. That is roughly 2375.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Strategic Partners A/S's current -485.57% should be judged against Healthcare norms (sector average: 21.34%) and against OZYMF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -485.57%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Strategic Partners A/S, and consider following OZYMF for alerts when major investors trade the stock.

Strategic Partners A/S is classified in the Healthcare sector. On profit margin, it currently shows -485.57% versus a sector average near 21.34%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing OZYMF with unrelated industries.